Literature DB >> 16099293

Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).

Michel Bolla1, Hein van Poppel, Laurence Collette, Paul van Cangh, Kris Vekemans, Luigi Da Pozzo, Theo M de Reijke, Antony Verbaeys, Jean-François Bosset, Roland van Velthoven, Jean-Marie Maréchal, Pierre Scalliet, Karin Haustermans, Marianne Piérart.   

Abstract

BACKGROUND: Local failure after prostatectomy can arise in patients with cancer extending beyond the capsule. We did a randomised controlled trial to compare radical prostatectomy followed by immediate external irradiation with prostatectomy alone for patients with positive surgical margin or pT3 prostate cancer.
METHODS: After undergoing radical retropubic prostatectomy, 503 patients were randomly assigned to a wait-and-see policy, and 502 to immediate postoperative radiotherapy (60 Gy conventional irradiation delivered over 6 weeks). Eligible patients had pN0M0 tumours and one or more pathological risk factors: capsule perforation, positive surgical margins, invasion of seminal vesicles. Our revised primary endpoint was biochemical progression-free survival. Analysis was by intention to treat.
FINDINGS: The median age was 65 years (IQR 61-69). After a median follow-up of 5 years, biochemical progression-free survival was significantly improved in the irradiated group (74.0%, 98% CI 68.7-79.3 vs 52.6%, 46.6-58.5; p<0.0001). Clinical progression-free survival was also significantly improved (p=0.0009). The cumulative rate of locoregional failure was significantly lower in the irradiated group (p<0.0001). Grade 2 or 3 late effects were significantly more frequent in the postoperative irradiation group (p=0.0005), but severe toxic toxicity (grade 3 or higher) were rare, with a 5-year rate of 2.6% in the wait-and-see group and 4.2% in the postoperative irradiation group (p=0.0726).
INTERPRETATION: Immediate external irradiation after radical prostatectomy improves biochemical progression-free survival and local control in patients with positive surgical margins or pT3 prostate cancer who are at high risk of progression. Further follow-up is needed to assess the effect on overall survival.

Entities:  

Mesh:

Year:  2005        PMID: 16099293     DOI: 10.1016/S0140-6736(05)67101-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  263 in total

Review 1.  Radical prostatectomy as primary treatment of high-risk prostate cancer.

Authors:  Alexandre Ingels; Alexandre de la Taille; Guillaume Ploussard
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

Review 2.  [Organ-limited prostate cancer with positive resection margins. Importance of adjuvant radiation therapy].

Authors:  D Porres; D Pfister; B Brehmer; A Heidenreich
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

3.  Opportunity lost and found: Any easy way to improve outcomes for prostate cancer patients in the postoperative setting?

Authors:  D Andrew Loblaw
Journal:  Can Urol Assoc J       Date:  2012-04       Impact factor: 1.862

Review 4.  Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling.

Authors:  Nitin Ohri; Adam P Dicker; Edouard J Trabulsi; Timothy N Showalter
Journal:  Eur J Cancer       Date:  2011-09-22       Impact factor: 9.162

Review 5.  [Current treatment of locally advanced and metastatic prostate cancer].

Authors:  Anton Ponholzer; Ferdinand Steinbacher; Stephan Madersbacher; Paul Schramek
Journal:  Wien Med Wochenschr       Date:  2011-08

6.  Shared responsibility for treatment-related morbidity for prostate cancer.

Authors:  Joseph L Chin; Glenn Bauman
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

7.  Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods.

Authors:  Ian M Thompson; Shady Salem; Sam S Chang; Peter E Clark; Rodney Davis; S Duke Herrell; Yakup Kordan; Roxelyn Baumgartner; Sharon Phillips; Joseph A Smith; Michael S Cookson; Daniel A Barocas
Journal:  World J Urol       Date:  2010-11-16       Impact factor: 4.226

8.  Radiation therapy in prostate cancer: a risk-adapted strategy.

Authors:  A J Hayden; C Catton; T Pickles
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

9.  Androgen deprivation therapy for prostate cancer-review of indications in 2010.

Authors:  H Quon; D A Loblaw
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

10.  Post-prostatectomy radiotherapy adversely affects urinary continence irrespective of radiotherapy regime.

Authors:  J N Nyarangi-Dix; J Steimer; T Bruckner; H Jakobi; S A Koerber; B Hadaschik; J Debus; M Hohenfellner
Journal:  World J Urol       Date:  2017-08-31       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.